Roivant Sciences Hits New 52-Week High at $30.03, Up 180.91%

Roivant Sciences has reached a significant milestone by hitting a new 52-week high of USD 30.03 on March 5, 2026. This achievement marks a remarkable increase in the stock's performance, reflecting a 180.91% rise over the past year, significantly outpacing the S&P 500's performance of 18.89% during the same period. As a mid-cap player in the Pharmaceuticals and Biotechnology industry, Roivant Sciences has a market capitalization of approximately USD 19,431 million. Despite its recent stock performance, the company is currently operating at a loss, as indicated by its negative price-to-earnings ratio and a return on equity of -26.15%. The stock's price-to-book ratio stands at 4.55, suggesting a premium valuation relative to its book value. With a debt-to-equity ratio of -1.06 and no dividend yield, Roivant Sciences continues to navigate the competitive landscape of the pharmaceuticals sector. The stock's previous 52-week low was recorded at USD 8.73, highlighting the significant upward movement it has experienced in recent months.